Skopinpharm is a Russian pharmaceutical company specializing in the development and GMP-compliant manufacture of high-quality finished dosage forms across a broad range of formulations. The company’s portfolio includes 28 medicinal products, with manufacturing capabilities covering more than 55 types of dosage forms for both the domestic market and international partners.

As a trusted contract manufacturing partner, Skopinpharm collaborates with leading international pharmaceutical companies, including Aspen, CSL Behring, Novartis, Octapharma, AstraZeneca, and Takeda, delivering pharmaceutical manufacturing services and advanced value-added solutions.

Skopinpharm is a key participant in major Special Investment Contracts (SPICs) with government and industry partners, aimed at developing full-cycle manufacturing capabilities, including biopharmaceutical products, plasma-derived medicines (including plasma collection centers), as well as oncology and hematology therapies.

Skopinpharm is a reliable partner for originators of orphan and high-cost medicines, providing rapid and structured access to the Russian market through federal and regional reimbursement programs. The company supports assets across the entire early access → registration → reimbursement pathway, including the supply of registered and unregistered medicines under the Circle of Good Foundation, the High-Cost Nosologies (HCN) Program, and regional reimbursement mechanisms. Skopinpharm has been a supplier to the Circle of Good Foundation since its first year of operation and has a proven track record of 50+ successful market entry cases over the past 10 years.

The company is headquartered in Moscow, with a manufacturing site located in Skopin, Ryazan Region, Russia. Skopinpharm combines robust manufacturing infrastructure with strict quality control systems aligned with international standards, supporting partner objectives in contract manufacturing and supply chain resilience.

Skopinpharm

Org chart

Teams

Offices